Coronary IVL
Commercial- Indications
- Coronary artery disease
Company intelligence / Profile preview
Shockwave Medical has commercialized its proprietary Intravascular Lithotripsy (IVL) system for the treatment of calcified cardiovascular and peripheral arterial diseases. The company’s IVL devices are widely adopted globally and have demonstrated strong clinical results in improving patient outcomes with a low risk of complications. The company also markets the Reducer device for refractory angina following its acquisition of Neovasc. As of early/mid–2024, more than $730 million in annual revenue was reported with continued global expansion and new product launches such as the Javelin and E8 catheters.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shockwave Medical.